T2加权与扩散加权MRI在前列腺癌IMRT局灶剂量提升前勾画前列腺内肿瘤的验证
该前瞻性研究纳入26例接受根治性放疗的前列腺癌患者,比较术前T2W+DW-MRI与5 mm间距经会阴模板引导穿刺活检对前列腺内肿瘤病灶的定位准确性。结果显示MRI对红色(临床显著)病灶的敏感度为85-86%、特异度为93-98%,观察者间一致性良好(Kappa 0.61),提示MRI可准确勾画临床显著前列腺癌,≥0.5 cm3的扩散受限病灶可用于放疗剂量提升。
要点
- MRI对红色影像定义病灶敏感度85-86%、特异度93-98%、PPV 79-92%、NPV 96%。
- 影像红色病灶与病理红色病灶相关性好(Reader 1 r=0.61,Reader 2 r=0.44)。
- 观察者间一致性良好,Cohen Kappa为0.61。
核心结论
- MRI对勾画临床显著前列腺癌是准确的,≥0.5 cm3的扩散受限病灶可被确信识别用于放疗剂量提升。
研究设计与样本
- 前瞻性招募26例选择根治性放疗的前列腺癌患者,行治疗前T2W+DW-MRI和5 mm间距经会阴模板引导前列腺穿刺活检。
- 采用交通灯系统对影像和病理数据评分,由两名放射科医生评估MRI并以Cohen Kappa衡量观察者间一致性。
主要发现
- 影像红色病灶(≥0.5 cm3)与活检病理红色病灶相关性好:Reader 1 r=0.61(p<0.0001),Reader 2 r=0.44(p=0.03)。
- 两名读者对红色影像定义病灶的敏感度85-86%、特异度93-98%、PPV 79-92%、NPV 96%。
- 观察者间一致性良好,Cohen Kappa为0.61。
关键数值与推荐
- 影像红色病灶定义为可疑病灶≥0.5 cm3;琥珀色为0.2-0.5 cm3可疑病灶或更大但肿瘤性质不确定的病灶。
- 病理红色定义为活检原发Gleason 4/5级且肿瘤长度≥4 mm,或原发Gleason 3级且肿瘤长度≥6 mm。
临床怎么用
- 对于计划接受局灶剂量提升的前列腺癌放疗患者,可利用T2W+DW-MRI识别≥0.5 cm3的扩散受限红色病灶进行靶区勾画。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: To assess the diagnostic accuracy and inter-observer agreement of T2-weighted (T2W) and diffusion-weighted (DW) magnetic resonance imaging (MRI) for mapping intra-prostatic tumour lesions (IPLs) for the purpose of focal dose-escalation in prostate cancer radiotherapy. MATERIALS AND METHODS: Twenty-six men selected for radical treatment with radiotherapy were recruited prospectively and underwent pre-treatment T2W+DW-MRI and 5 mm spaced transperineal template-guided mapping prostate biopsies (TTMPB). A 'traffic-light' system was used to score both data sets. Radiologically suspicious lesions measuring ≥0.5 cm3 were classified as red; suspicious lesions 0.2-0.5 cm3 or larger lesions equivocal for tumour were classified as amber. The histopathology assessment combined pathological grade and tumour length on biopsy (red = ≥4 mm primary Gleason grade 4/5 or ≥6 mm primary Gleason grade 3). Two radiologists assessed the MRI data and inter-observer agreement was measured with Cohens' Kappa co-efficient. RESULTS: Twenty-five of 26 men had red image-defined IPLs by both readers, 24 had red pathology-defined lesions. There was a good correlation between lesions ≥0.5 cm3 classified "red" on imaging and "red" histopathology in biopsies (Reader 1: r = 0.61, p < 0.0001, Reader 2: r = 0.44, p = 0.03). Diagnostic accuracy for both readers for red image-defined lesions was sensitivity 85-86%, specificity 93-98%, positive predictive value (PPV) 79-92% and negative predictive value (NPV) 96%. Inter-observer agreement was good (Cohen's Kappa 0.61). CONCLUSIONS: MRI is accurate for mapping clinically significant prostate cancer; diffusion-restricted lesions ≥0.5 cm3 can be confidently identified for radiation dose boosting.
引用
- Alexander EJ, Murray JR, Morgan VA, et al. Validation of T2- and diffusion-weighted magnetic resonance imaging for mapping intra-prostatic tumour prior to focal boost dose-escalation using intensity-modulated radiotherapy (IMRT). Radiother Oncol. 2019. PMID: 31493904. doi:10.1016/j.radonc.2019.07.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。